他汀类药物使用提高纳武利尤单抗在晚期肾细胞癌患者中的疗效
回顾性分析意大利、西班牙和美国十家机构219例接受二线或三线纳武利尤单抗治疗的转移性肾细胞癌患者,其中59例(27%)为他汀使用者。他汀使用者中位总生存期(34.4个月对18.6个月,p=0.017)和中位无进展生存期(11.7个月对4.6个月,p=0.013)较长,总体临床获益较高(71%对54%,p=0.030)。作者认为他汀使用对该人群具有预后影响。
要点
- 他汀使用者中位总生存期34.4个月,非使用者18.6个月(p=0.017)。
- 他汀使用者中位无进展生存期11.7个月,非使用者4.6个月(p=0.013)。
- 他汀使用者总体临床获益71%,非使用者54%(p=0.030)。
核心结论
- 本研究提示他汀使用对接受纳武利尤单抗治疗的转移性肾细胞癌患者具有预后影响。
研究设计与样本
- 回顾性审查意大利、西班牙和美国十家机构2016年1月至2021年9月间接受二线或三线纳武利尤单抗治疗的转移性肾细胞癌患者病历。
- 共219例患者纳入分析,其中59例(27%)为他汀使用者。
- 评估总生存期、无进展生存期和总体临床获益,采用单因素和多因素分析探索相关变量与生存的关联。
主要发现
- 他汀使用者中位总生存期34.4个月,非使用者18.6个月(p=0.017)。
- 他汀使用者中位无进展生存期11.7个月,非使用者4.6个月(p=0.013)。
- 年龄≥70岁患者中,他汀使用者中位总生存期21.4个月,非使用者10.1个月(p=0.047);中位无进展生存期16.4个月对4.6个月(p=0.022)。
- 年龄<70岁患者中,他汀使用者中位总生存期34.4个月,非使用者21.4个月(p=0.043);中位无进展生存期10.3个月对4.6个月(p=0.042)。
- 他汀使用者总体临床获益71%,非使用者54%(p=0.030)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Statins are widely used in an ageing population, including subjects with solid malignancies. However, no conclusive evidence is currently available on their potential influence on patients' outcome. We aimed to assess whether statin exposure affects the survival of patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. PATIENTS AND METHODS: Medical records of patients with documented mRCC treated with second- or third-line nivolumab were reviewed at ten institutions from Italy, Spain and the USA. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit. Univariate and multivariate analyses were used to explore the association of variables of interest with survival. RESULTS: A total of 219 patients with mRCC receiving nivolumab between January 2016 and September 2021 were eligible for inclusion in this study; 59 (27%) were statin users. The median OS (34.4 versus 18.6 months, p = 0.017) and PFS (11.7 versus 4.6 months, p = 0.013) resulted apparently longer in statin users. Stratified by age, longer median OS and PFS were associated with statin exposure in both patients aged ≥70 y (median OS: 21.4 versus 10.1 months, p = 0.047; median PFS: 16.4 versus 4.6 months, p = 0.022) and <70 y (median OS: 34.4 versus 21.4 months, p = 0.043; median PFS: 10.3 versus 4.6 months, p = 0.042). Overall clinical benefit resulted higher in statin users than non-users (71% versus 54%, p = 0.030). CONCLUSIONS: Our study suggests a prognostic impact of statin use in patients receiving nivolumab for mRCC.
引用
- Santoni M, Massari F, Matrana MR, et al. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. Eur J Cancer. 2022. PMID: 35780525. doi:10.1016/j.ejca.2022.04.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。